Widely used:Recently Viewed
Clear AllValue Research Rating
Quality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
₹704 Cr
P/E Ratio
21.56
P/B Ratio
2.5
Industry P/E
51.72
Debt to Equity
0.13
ROE
17.03 %
ROCE
20.38 %
Div. Yield
0.15 %
Book Value
455.77
EPS
52.82
CFO
₹174.46 Cr
EBITDA
₹373.01 Cr
Net Profit
₹244.14 Cr
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
NGL Fine-Chem
| -38.98 | -2.46 | -33.03 | -58.17 | -- | -- | -- |
|
BSE Healthcare
| -6.14 | 2.34 | 5.29 | 19.62 | 20.23 | 22.45 | 10.19 |
|
BSE Small Cap
| -11.66 | 3.78 | 1.91 | 2.46 | 18.92 | 34.83 | 16.14 |
|
2024
|
2023
|
|
|---|---|---|
|
NGL Fine-Chem
| -16.17 | 45.20 |
|
BSE Small Cap
| 29.04 | 47.52 |
|
BSE Healthcare
| 43.09 | 36.97 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | P/E Ratio | ROE |
|---|---|---|---|---|
| 1,109.30 | 9,005.58 | 74.19 | 12.96 | |
| 458.55 | 11,287.98 | 23.56 | 14.4 | |
| 1,876.10 | 1,629.06 | 52.3 | 10.49 | |
| 147.94 | 3,757.03 | 322.52 | 1.73 |
NGL Fine-Chem Limited manufactures and sells pharmaceuticals and intermediates for use in veterinary and human health worldwide. The company offers animal health pharmaceutical ingredients, such as diminazene aceturate, diminazene diaceturate,... homidium chloride, nitroxynil, clorsulon, parvaquone, buparvaquone, isometamidium chloride hydrochloride, toldimfos sodium, butaphosphan, imidocarb dipropionate, triclabendazole, ractopamine hcl, s-methoprene, toltrazuril, decoquinate, amitraz, marbofloxacin, flunixin meglumine, praziquantel, carprofen, fenbendazole, and xylazine hydrochloride. It also offers human health pharmaceutical ingredients comprising of nitazoxanide and atovaquone; and intermediates and specialty chemicals consisting of trimethyl, triazacylononane, and ethyl glucamine. In addition, the company provides finished dosage forms comprising of diminazene aceturate granules and homidium chloride tablets. NGL Fine-Chem Limited was incorporated in 1981 and is based in Mumbai, India. Read more
Incorporated
1981
Chairman
Dhananjay Mungale
Managing Director
Rahul J Nachane
Headquarters
Mumbai, Maharashtra
Website
Our rating system has guided millions of investors in the past 20 years.
Annual Reports
The total asset value of NGL Fine-Chem Ltd stood at ₹ 396 Cr as on 31-Dec-24
The share price of NGL Fine-Chem Ltd is ₹1,105.10 (NSE) and ₹1,120.00 (BSE) as of 29-Apr-2025 10:49 IST. NGL Fine-Chem Ltd has given a return of -58.17% in the last 1 years.
NGL Fine-Chem Ltd has a market capitalisation of ₹ 704 Cr as on 29-Apr-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of NGL Fine-Chem Ltd is 2.50 times as on 29-Apr-2025, a 67% discount to its peers’ median range of 7.57 times.
The P/E ratio of NGL Fine-Chem Ltd is 21.56 times as on 29-Apr-2025, a 58% discount to its peers’ median range of 51.72 times.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the NGL Fine-Chem Ltd and enter the required number of quantities and click on buy to purchase the shares of NGL Fine-Chem Ltd.
NGL Fine-Chem Limited manufactures and sells pharmaceuticals and intermediates for use in veterinary and human health worldwide. The company offers animal health pharmaceutical ingredients, such as diminazene aceturate, diminazene diaceturate, homidium chloride, nitroxynil, clorsulon, parvaquone, buparvaquone, isometamidium chloride hydrochloride, toldimfos sodium, butaphosphan, imidocarb dipropionate, triclabendazole, ractopamine hcl, s-methoprene, toltrazuril, decoquinate, amitraz, marbofloxacin, flunixin meglumine, praziquantel, carprofen, fenbendazole, and xylazine hydrochloride. It also offers human health pharmaceutical ingredients comprising of nitazoxanide and atovaquone; and intermediates and specialty chemicals consisting of trimethyl, triazacylononane, and ethyl glucamine. In addition, the company provides finished dosage forms comprising of diminazene aceturate granules and homidium chloride tablets. NGL Fine-Chem Limited was incorporated in 1981 and is based in Mumbai, India.
The prominent promoters of NGL Fine-Chem Ltd. are
| Name of promoters | Holding percentage |
|---|---|
|
RAJESH LAWANDE |
21.89%
|
|
RAHUL NACHANE |
17.54%
|
|
SUNITA POTDAR |
13.38%
|
|
AJITA NACHANE |
11.55%
|
|
PCI FERRMONE CHEMICALS (INDIA) PVT LTD |
8.38%
|
The chairman of the company is Dhananjay Mungale, and the managing director is Rahul J Nachane.
There is no promoter pledging in NGL Fine-Chem Ltd.
Some of the close peers are:
| Company | Market Cap(₹ Cr) |
|---|---|
|
3,709
|
|
|
1,655
|
|
|
10,968
|
|
|
8,743
|
| NGL Fine-Chem Ltd. | Ratios |
|---|---|
|
Return on equity(%)
|
12.02
|
|
Operating margin(%)
|
7.98
|
|
Net Margin(%)
|
8.42
|
|
Dividend yield(%)
|
0.16
|
Yes, TTM profit after tax of NGL Fine-Chem Ltd was ₹33 Cr.
₹-13.90
(
